Goldman JG, Postuma R. Premotor and non-motor features of
Parkinson’s disease. Curr Opin Neurol. 2014;27(4):434–41.
PubMed
PubMed Central
Google Scholar
Lyons KE, Pahwa R. The impact and management of non-motor symptoms
of Parkinson’s disease. Am J Manag Care. 2011;17[Suppl
12]:S308–14.
PubMed
Google Scholar
Wen MC, Chan LL, Tan LC, Tan EK. Depression, anxiety, and apathy in
Parkinson’s disease: insights from neuroimaging studies. Eur J Neurol.
2016;23(6):1001–19.
PubMed
Google Scholar
Ziemssen T, Reichmann H. Non-motor dysfunction in Parkinson’s
disease. Parkinson Relat Disord. 2007;13(6):323–32.
Google Scholar
Goldstein DS. Dysautonomia in Parkinson disease. Compr Physiol.
2014;4(2):805–26.
PubMed
PubMed Central
Google Scholar
Dickson DW. Parkinson’s disease and parkinsonism: neuropathology.
Cold Spring Harb Perspect Med. 2012;2(8):a009258.
PubMed
PubMed Central
Google Scholar
Coon EA, Cutsforth-Gregory JK, Benarroch EE. Neuropathology of
autonomic dysfunction in synucleinopathies. Mov Disord.
2018;33(3):349–58.
PubMed
Google Scholar
Kaufmann H, Goldstein DS. Autonomic dysfunction in Parkinson
disease. Handb Clin Neurol. 2013;117:259–78.
PubMed
Google Scholar
Gibbons CH, Schmidt P, Biaggioni I, et al. The recommendations of a
consensus panel for the screening, diagnosis, and treatment of neurogenic
orthostatic hypotension and associated supine hypertension. J Neurol.
2017;264(8):1567–82.
PubMed
PubMed Central
Google Scholar
Freeman R, Wieling W, Axelrod FB, et al. Consensus statement on the
definition of orthostatic hypotension, neurally mediated syncope and the
postural tachycardia syndrome. Clin Auton Res.
2011;21(2):69–72.
PubMed
Google Scholar
Isaacson SH, Skettini J. Neurogenic orthostatic hypotension in
Parkinson’s disease: evaluation, management, and emerging role of droxidopa.
Vasc Health Risk Manag. 2014;10:169–76.
PubMed
PubMed Central
Google Scholar
Claassen DO, Adler CH, Hewitt LA, Gibbons C. Characterization of
the symptoms of neurogenic orthostatic hypotension and their impact from a
survey of patients and caregivers. BMC Neurol. 2018;18(1):125.
PubMed
PubMed Central
Google Scholar
Goldstein DS, Sharabi Y. Neurogenic orthostatic hypotension: a
pathophysiological approach. Circulation. 2009;119(1):139–46.
PubMed
PubMed Central
Google Scholar
Jones PK, Shaw BH, Raj SR. Orthostatic hypotension: managing a
difficult problem. Expert Rev Cardiovasc Ther.
2015;13(11):1263–76.
CAS
PubMed
PubMed Central
Google Scholar
Brignole M, Moya A, de Lange FJ, et al. 2018 ESC guidelines for the
diagnosis and management of syncope. Eur Heart J.
2018;39(21):1883–948.
PubMed
Google Scholar
Wieling W, Krediet CT, van Dijk N, Linzer M, Tschakovsky ME.
Initial orthostatic hypotension: review of a forgotten condition. Clin Sci
(Lond). 2007;112(3):157–65.
PubMed
Google Scholar
Freeman R. Clinical practice. Neurogenic orthostatic hypotension. N
Engl J Med. 2008;358(6):615–24.
CAS
PubMed
Google Scholar
Moya A, Sutton R, Ammirati F, et al. Guidelines for the diagnosis
and management of syncope (version 2009): the Task Force for the Diagnosis and
Management of Syncope of the European Society of Cardiology (ESC). Eur Heart J.
2009;30(21):2631–71.
PubMed
PubMed Central
Google Scholar
Stewart JM, Clarke D. “He’s dizzy when he stands up”: an
introduction to initial orthostatic hypotension. J Pediatr.
2011;158(3):499–504.
PubMed
PubMed Central
Google Scholar
Kaufmann H, Norcliffe-Kaufmann L, Palma JA. Droxidopa in neurogenic
orthostatic hypotension. Expert Rev Cardiovasc Ther.
2015;13(8):875–91.
CAS
PubMed
PubMed Central
Google Scholar
Low PA, Singer W. Management of neurogenic orthostatic hypotension:
an update. Lancet Neurol. 2008;7(5):451–8.
PubMed
PubMed Central
Google Scholar
Low PA. Neurogenic orthostatic hypotension: pathophysiology and
diagnosis. Am J Manag Care. 2015;21[13 Suppl]:s248–57.
PubMed
Google Scholar
Robertson D. The pathophysiology and diagnosis of orthostatic
hypotension. Clin Auton Res. 2008;18[Suppl 1]:2–7.
PubMed
Google Scholar
Freeman R, Abuzinadah AR, Gibbons C, Jones P, Miglis MG, Sinn DI.
Orthostatic hypotension: JACC state-of-the-art review. J Am Coll Cardiol.
2018;72(11):1294–309.
PubMed
Google Scholar
Velseboer DC, de Haan RJ, Wieling W, Goldstein DS, de Bie RM.
Prevalence of orthostatic hypotension in Parkinson’s disease: a systematic
review and meta-analysis. Parkinson Relat Disord.
2011;17(10):724–9.
Google Scholar
Palma JA, Gomez-Esteban JC, Norcliffe-Kaufmann L, et al.
Orthostatic hypotension in Parkinson disease: how much you fall or how low you
go? Mov Disord. 2015;30(5):639–45.
PubMed
PubMed Central
Google Scholar
Merola A, Romagnolo A, Rosso M, et al. Autonomic dysfunction in
Parkinson’s disease: a prospective cohort study. Mov Disord.
2018;33(3):391–7.
PubMed
Google Scholar
Ha AD, Brown CH, York MK, Jankovic J. The prevalence of symptomatic
orthostatic hypotension in patients with Parkinson’s disease and atypical
parkinsonism. Parkinson Relat Disord. 2011;17(8):625–8.
Google Scholar
Senard JM, Rai S, Lapeyre-Mestre M, et al. Prevalence of
orthostatic hypotension in Parkinson’s disease. J Neurol Neurosurg Psychiatry.
1997;63(5):584–9.
CAS
PubMed
PubMed Central
Google Scholar
Merola A, Romagnolo A, Rosso M, et al. Orthostatic hypotension in
Parkinson’s disease: does it matter if asymptomatic? Parkinson Relat Disord.
2016;33:65–71.
Google Scholar
Palma JA, Kaufmann H. Epidemiology, diagnosis, and management of
neurogenic orthostatic hypotension. Mov Disord Clin Pract.
2017;4(3):298–308.
PubMed
PubMed Central
Google Scholar
Gibbons CH, Freeman R. Clinical implications of delayed orthostatic
hypotension: a 10-year follow-up study. Neurology.
2015;85(16):1362–7.
PubMed
PubMed Central
Google Scholar
Finucane C, O’Connell MD, Donoghue O, Richardson K, Savva GM, Kenny
RA. Impaired orthostatic blood pressure recovery is associated with unexplained
and injurious falls. J Am Geriatr Soc. 2017;65(3):474–82.
PubMed
Google Scholar
Verbaan D, Marinus J, Visser M, van Rooden SM, Stiggelbout AM, van
Hilten JJ. Patient-reported autonomic symptoms in Parkinson disease. Neurology.
2007;69(4):333–41.
CAS
PubMed
Google Scholar
Berg D, Postuma RB, Adler CH, et al. MDS research criteria for
prodromal Parkinson’s disease. Mov Disord.
2015;30(12):1600–11.
PubMed
Google Scholar
Fereshtehnejad SM, Lokk J. Orthostatic hypotension in patients with
Parkinson’s disease and atypical parkinsonism. Parkinsons Dis.
2014;2014:475854.
PubMed
PubMed Central
Google Scholar
Goldstein DS. Orthostatic hypotension as an early finding in
Parkinson’s disease. Clin Auton Res. 2006;16(1):46–54.
PubMed
Google Scholar
Goldstein DS, Sharabi Y, Karp BI, et al. Cardiac sympathetic
denervation preceding motor signs in Parkinson disease. Clin Auton Res.
2007;17(2):118–21.
PubMed
PubMed Central
Google Scholar
Milazzo V, Di Stefano C, Servo S, Zibetti M, Lopiano L, Maule S.
Neurogenic orthostatic hypotension as the initial feature of Parkinson disease.
Clin Auton Res. 2012;22(4):203–6.
PubMed
Google Scholar
Schrag A, Horsfall L, Walters K, Noyce A, Petersen I. Prediagnostic
presentations of Parkinson’s disease in primary care: a case–control study.
Lancet Neurol. 2015;14(1):57–64.
PubMed
Google Scholar
Kaufmann H, Nahm K, Purohit D, Wolfe D. Autonomic failure as the
initial presentation of Parkinson disease and dementia with Lewy bodies.
Neurology. 2004;63(6):1093–5.
PubMed
Google Scholar
Nylin G, Levander M. Studies on the circulation with the aid of
tagged erythrocytes in a case of orthostatic hypotension (asympathicotomic
hypotension). Ann Intern Med. 1948;28(4):723–46.
CAS
PubMed
Google Scholar
Singer W, Berini SE, Sandroni P, et al. Pure autonomic failure:
predictors of conversion to clinical CNS involvement. Neurology.
2017;88(12):1129–36.
PubMed
PubMed Central
Google Scholar
Giannini G, Calandra-Buonaura G, Asioli GM, et al. The natural
history of idiopathic autonomic failure: the IAF-BO cohort study. Neurology.
2018;91(13):e1245–54.
PubMed
Google Scholar
Kaufmann H, Norcliffe-Kaufmann L, Palma JA, et al. Natural history
of pure autonomic failure: a United States prospective cohort. Ann Neurol.
2017;81(2):287–97.
PubMed
PubMed Central
Google Scholar
Fereshtehnejad SM, Romenets SR, Anang JB, Latreille V, Gagnon JF,
Postuma RB. New clinical subtypes of Parkinson disease and their longitudinal
progression: a prospective cohort comparison with other phenotypes. JAMA Neurol.
2015;72(8):863–73.
PubMed
Google Scholar
Goldstein DS, Holmes C, Sharabi Y, Wu T. Survival in
synucleinopathies: a prospective cohort study. Neurology.
2015;85(18):1554–61.
CAS
PubMed
PubMed Central
Google Scholar
Fanciulli A, Jordan J, Biaggioni I, et al. Consensus statement on
the definition of neurogenic supine hypertension in cardiovascular autonomic
failure by the American Autonomic Society (AAS) and the European Federation of
Autonomic Societies (EFAS): endorsed by the European Academy of Neurology (EAN)
and the European Society of Hypertension (ESH). Clin Auton Res.
2018;28(4):355–62.
PubMed
PubMed Central
Google Scholar
Fanciulli A, Gobel G, Ndayisaba JP, et al. Supine hypertension in
Parkinson’s disease and multiple system atrophy. Clin Auton Res.
2016;26(2):97–105.
PubMed
Google Scholar
Baker J, Kimpinski K. Management of supine hypertension
complicating neurogenic orthostatic hypotension. CNS Drugs.
2017;31(8):653–63.
CAS
PubMed
Google Scholar
Sharabi Y, Goldstein DS. Mechanisms of orthostatic hypotension and
supine hypertension in Parkinson disease. J Neurol Sci.
2011;310(1–2):123–8.
PubMed
PubMed Central
Google Scholar
Garland EM, Gamboa A, Okamoto L, et al. Renal impairment of pure
autonomic failure. Hypertension. 2009;54(5):1057–61.
CAS
PubMed
PubMed Central
Google Scholar
Maule S, Milan A, Grosso T, Veglio F. Left ventricular hypertrophy
in patients with autonomic failure. Am J Hypertens.
2006;19(10):1049–54.
PubMed
Google Scholar
Vagaonescu TD, Saadia D, Tuhrim S, Phillips RA, Kaufmann H.
Hypertensive cardiovascular damage in patients with primary autonomic failure.
Lancet. 2000;355(9205):725–6.
CAS
PubMed
Google Scholar
Milazzo V, Maule S, Di Stefano C, et al. Cardiac organ damage and
arterial stiffness in autonomic failure: comparison with essential hypertension.
Hypertension. 2015;66(6):1168–75.
CAS
PubMed
Google Scholar
Palma JA, Redel-Traub G, Porciuncula A, et al. The impact of supine
hypertension on target organ damage and mortality in patients with neurogenic
orthostatic hypotension. Clin Auton Res. 2018;28:473.
Google Scholar
Plaschke M, Trenkwalder P, Dahlheim H, Lechner C, Trenkwalder C.
Twenty-four-hour blood pressure profile and blood pressure responses to head-up
tilt tests in Parkinson’s disease and multiple system atrophy. J Hypertens.
1998;16(10):1433–41.
CAS
PubMed
Google Scholar
Okamoto LE, Gamboa A, Shibao C, et al. Nocturnal blood pressure
dipping in the hypertension of autonomic failure. Hypertension.
2009;53(2):363–9.
CAS
PubMed
Google Scholar
Kaufmann H, Norcliffe-Kaufmann L, Hewitt LA, Rowse GJ, White WB.
Effects of the novel norepinephrine prodrug, droxidopa, on ambulatory blood
pressure in patients with neurogenic orthostatic hypotension. J Am Soc
Hypertens. 2016;10(10):819–26.
CAS
PubMed
Google Scholar
Milazzo V, Di Stefano C, Vallelonga F, et al. Reverse blood
pressure dipping as marker of dysautonomia in Parkinson disease. Parkinson Relat
Disord. 2018;56:82–7.
Google Scholar
Routledge FS, McFetridge-Durdle JA, Dean CR. Night-time blood
pressure patterns and target organ damage: a review. Can J Cardiol.
2007;23(2):132–8.
PubMed
PubMed Central
Google Scholar
Tan LC, Tan AK, Tjia HT. The profile of hospitalised patients with
Parkinson’s disease. Ann Acad Med Singapore.
1998;27(6):808–12.
CAS
PubMed
Google Scholar
Woodford H, Walker R. Emergency hospital admissions in idiopathic
Parkinson’s disease. Mov Disord. 2005;20(9):1104–8.
PubMed
Google Scholar
Rudzinska M, Bukowczan S, Stozek J, et al. Causes and consequences
of falls in Parkinson disease patients in a prospective study. Neurol Neurochir
Pol. 2013;47(5):423–30.
CAS
PubMed
Google Scholar
Francois C, Biaggioni I, Shibao C, et al. Fall-related healthcare
use and costs in neurogenic orthostatic hypotension with Parkinson’s disease. J
Med Econ. 2017;20(5):525–32.
PubMed
Google Scholar
Tinetti ME, Williams CS. Falls, injuries due to falls, and the risk
of admission to a nursing home. N Engl J Med.
1997;337(18):1279–84.
CAS
PubMed
Google Scholar
Magerkurth C, Schnitzer R, Braune S. Symptoms of autonomic failure
in Parkinson’s disease: prevalence and impact on daily life. Clin Auton Res.
2005;15(2):76–82.
PubMed
Google Scholar
McDonell KE, Shibao CA, Claassen DO. Clinical relevance of
orthostatic hypotension in neurodegenerative disease. Curr Neurol Neurosci Rep.
2015;15(12):78.
PubMed
Google Scholar
Merola A, Sawyer RP, Artusi CA, et al. Orthostatic hypotension in
Parkinson disease: impact on health care utilization. Parkinson Relat Disord.
2017;47:45–9.
Google Scholar
McNicholas T, Tobin K, Carey D, O’Callaghan S, Kenny RA. Is
baseline orthostatic hypotension associated with a decline in global cognitive
performance at 4-year follow-up? Data from TILDA (The Irish Longitudinal Study
on Ageing). J Am Heart Assoc. 2018;7(19):e008976.
PubMed
PubMed Central
Google Scholar
Udow SJ, Robertson AD, MacIntosh BJ, et al. ‘Under pressure’: is
there a link between orthostatic hypotension and cognitive impairment in
alpha-synucleinopathies? J Neurol Neurosurg Psychiatry.
2016;87(12):1311–21.
PubMed
Google Scholar
McDonald C, Newton JL, Burn DJ. Orthostatic hypotension and
cognitive impairment in Parkinson’s disease: causation or association? Mov
Disord. 2016;31(7):937–46.
CAS
PubMed
Google Scholar
Centi J, Freeman R, Gibbons CH, Neargarder S, Canova AO,
Cronin-Golomb A. Effects of orthostatic hypotension on cognition in Parkinson
disease. Neurology. 2017;88(1):17–24.
PubMed
PubMed Central
Google Scholar
Schrezenmaier C, Gehrking JA, Hines SM, Low PA, Benrud-Larson LM,
Sandroni P. Evaluation of orthostatic hypotension: relationship of a new
self-report instrument to laboratory-based measures. Mayo Clin Proc.
2005;80(3):330–4.
PubMed
Google Scholar
Kaufmann H, Malamut R, Norcliffe-Kaufmann L, Rosa K, Freeman R. The
Orthostatic Hypotension Questionnaire (OHQ): validation of a novel symptom
assessment scale. Clin Auton Res. 2012;22(2):79–90.
PubMed
Google Scholar
Shibao C, Lipsitz LA, Biaggioni I. ASH position paper: evaluation
and treatment of orthostatic hypotension. J Clin Hypertens (Greenwich).
2013;15(3):147–53.
CAS
Google Scholar
Shaw BH, Garland EM, Black BK, et al. Optimal diagnostic thresholds
for diagnosis of orthostatic hypotension with a ‘sit-to-stand test’. J
Hypertens. 2017;35(5):1019–25.
CAS
PubMed
PubMed Central
Google Scholar
Loew F, Gauthey L, Koerffy A, et al. Postprandial hypotension and
orthostatic blood pressure responses in elderly Parkinson’s disease patients. J
Hypertens. 1995;13(11):1291–7.
CAS
PubMed
Google Scholar
Micieli G, Martignoni E, Cavallini A, Sandrini G, Nappi G.
Postprandial and orthostatic hypotension in Parkinson’s disease. Neurology.
1987;37(3):386–93.
CAS
PubMed
Google Scholar
van Twist DJL, Dinh T, Bouwmans EME, Kroon AA. Initial orthostatic
hypotension among patients with unexplained syncope: an overlooked diagnosis?
Int J Cardiol. 2018;271:269–73.
PubMed
Google Scholar
Norcliffe-Kaufmann L, Kaufmann H, Palma JA, et al. Orthostatic
heart rate changes in patients with autonomic failure caused by
neurodegenerative synucleinopathies. Ann Neurol.
2018;83(3):522–31.
PubMed
PubMed Central
Google Scholar
Balagny P, Wanono R, d’Ortho MP, Vidal-Petiot E. Reply to
validation of the new diagnostic tests for neurogenic orthostatic hypotension.
Ann Neurol. 2018;84(6):957–8.
PubMed
Google Scholar
Metzler M, Duerr S, Granata R, Krismer F, Robertson D, Wenning GK.
Neurogenic orthostatic hypotension: pathophysiology, evaluation, and management.
J Neurol. 2013;260(9):2212–9.
PubMed
Google Scholar
Low PA, Tomalia VA, Park KJ. Autonomic function tests: some
clinical applications. J Clin Neurol. 2013;9(1):1–8.
PubMed
PubMed Central
Google Scholar
Loavenbruck A, Sandroni P. Neurogenic orthostatic hypotension:
roles of norepinephrine deficiency in its causes, its treatment, and future
research directions. Curr Med Res Opin. 2015;31(11):2095–104.
PubMed
Google Scholar
Lipp A, Sandroni P, Ahlskog JE, et al. Prospective differentiation
of multiple system atrophy from Parkinson disease, with and without autonomic
failure. Arch Neurol. 2009;66(6):742–50.
PubMed
PubMed Central
Google Scholar
Low PA. Composite autonomic scoring scale for laboratory
quantification of generalized autonomic failure. Mayo Clin Proc.
1993;68(8):748–52.
CAS
PubMed
Google Scholar
Camerlingo M, Ferraro B, Gazzaniga GC, Casto L, Cesana BM, Mamoli
A. Cardiovascular reflexes in Parkinson’s disease: long-term effects of levodopa
treatment on de novo patients. Acta Neurol Scand.
1990;81(4):346–8.
CAS
PubMed
Google Scholar
Calne DB, Brennan J, Spiers AS, Stern GM. Hypotension caused
by L-dopa. Br Med J.
1970;1(5694):474–5.
CAS
PubMed
PubMed Central
Google Scholar
Jost WH, Bellon AK, Kaiser T, Schrank B. The impact of ropinirole
on blood pressure and noradrenaline concentration after active orthostasis in
Parkinsonian patients. Parkinson Relat Disord. 1998;4(2):61–3.
CAS
Google Scholar
Bouhaddi M, Vuillier F, Fortrat JO, et al. Impaired cardiovascular
autonomic control in newly and long-term-treated patients with Parkinson’s
disease: involvement of L-dopa therapy.
Auton Neurosci. 2004;116(1–2):30–8.
CAS
PubMed
Google Scholar
Barbeau A. L-dopa therapy in
Parkinson’s disease: a critical review of nine years’ experience. Can Med Assoc
J. 1969;101(13):59–68.
CAS
PubMed
PubMed Central
Google Scholar
Haapaniemi TH, Kallio MA, Korpelainen JT, et al. Levodopa,
bromocriptine and selegiline modify cardiovascular responses in Parkinson’s
disease. J Neurol. 2000;247(11):868–74.
CAS
PubMed
Google Scholar
Churchyard A, Mathias CJ, Lees AJ. Selegiline-induced postural
hypotension in Parkinson’s disease: a longitudinal study on the effects of drug
withdrawal. Mov Disord. 1999;14(2):246–51.
CAS
PubMed
Google Scholar
Boehringer Ingelheim Pharmaceuticals, Inc. Miraprex® (pramipexole
dihydrochloride). Full prescribing information. Ridgefield: Boehringer Ingelheim
Pharmaceuticals, Inc; 2007.
Google Scholar
Boehringer Ingelheim Pharmaceuticals, Inc. Miraprex ER®
(pramipexole dihydrochloride). Full prescribing information. Ridgefield:
Boehringer Ingelheim Pharmaceuticals, Inc; 2014.
Google Scholar
Novartis International AG. Parlodel® (Bromocriptine mesylate). Full
prescribing information. Suffern: Novartis International AG;
2011.
Google Scholar
Teva Pharmaceuticals. Rasagiline (rasagiline). Full prescribing
information. Parsippany: Teva Pharmaceuticals; 2019.
Google Scholar
GlaxoSmithKline. REQUIP (ropinirole). Full prescribing information.
Research Triangle Park: GlaxoSmithKline; 2018.
Google Scholar
Merck & Co., Inc. Sinemet® (carbidopa levodopa). Full
prescribing information. Whitehouse Station: Merck & Co., Inc.; 2018. https://www.merck.com/product/usa/pi_circulars/s/sinemet/sinemet_pi.pdf
Google Scholar
Valeant Pharmaceuticals. ZELAPAR® (selegiline hydrochloride). Full
prescribing information. Aliso Viejo: Valeant Pharmaceuticals;
2008.
Google Scholar
Adamas Pharma, LLC. GOCOVRI™ (amantadine). Full prescribing
information. Emeryville: Adamas Pharma, LLC; 2017.
Google Scholar
Pahwa R, Tanner CM, Hauser RA, et al. ADS-5102 (amantadine)
extended-release capsules for levodopa-induced dyskinesia in Parkinson disease
(EASE LID Study): a randomized clinical trial. JAMA Neurol.
2017;74(8):941–9.
PubMed
PubMed Central
Google Scholar
Oertel W, Eggert K, Pahwa R, et al. Randomized, placebo-controlled
trial of ADS-5102 (amantadine) extended-release capsules for levodopa-induced
dyskinesia in Parkinson’s disease (EASE LID 3). Mov Disord.
2017;32(12):1701–9.
CAS
PubMed
PubMed Central
Google Scholar
Goldstein DS, Eldadah BA, Holmes C, et al. Neurocirculatory
abnormalities in Parkinson disease with orthostatic hypotension: independence
from levodopa treatment. Hypertension. 2005;46(6):1333–9.
CAS
PubMed
Google Scholar
Kim JS, Lee SH, Oh YS, et al. Cardiovascular autonomic dysfunction
in mild and advanced Parkinson’s disease. J Mov Disord.
2016;9(2):97–103.
PubMed
PubMed Central
Google Scholar
Korchounov A, Kessler KR, Schipper HI. Differential effects of
various treatment combinations on cardiovascular dysfunction in patients with
Parkinson’s disease. Acta Neurol Scand. 2004;109(1):45–51.
CAS
PubMed
Google Scholar
Shen WK, Sheldon RS, Benditt DG, et al. 2017 ACC/AHA/HRS guideline
for the evaluation and management of patients with syncope: a report of the
American College of Cardiology/American Heart Association Task Force on clinical
practice guidelines and the Heart Rhythm Society. J Am Coll Cardiol.
2017;70(5):e39–110.
PubMed
Google Scholar
Craig GM. Clinical presentation of orthostatic hypotension in the
elderly. Postgrad Med J. 1994;70(827):638–42.
CAS
PubMed
PubMed Central
Google Scholar
Perez-Lloret S, Rey MV, Fabre N, et al. Factors related to
orthostatic hypotension in Parkinson’s disease. Parkinson Relat Disord.
2012;18(5):501–5.
Google Scholar
Newton JL, Frith J. The efficacy of non-pharmacologic intervention
for orthostatic hypotension associated with aging. Neurology.
2018;91(7):e652–6.
PubMed
PubMed Central
Google Scholar
Mills PB, Fung CK, Travlos A, Krassioukov A. Nonpharmacologic
management of orthostatic hypotension: a systematic review. Arch Phys Med
Rehabil. 2015;96(2):366–75.
PubMed
Google Scholar
Lundbeck NA Ltd. NORTHERA® (droxidopa).
Deerfield: Lundbeck NA Ltd; 2017.
Google Scholar
Shire US Inc. ProAmatine® (midodrine
hydrochloride). Full prescribing information. Lexington: Shire US Inc.;
2017.
Google Scholar
Hauser RA, Isaacson S, Lisk JP, Hewitt LA, Rowse G. Droxidopa for
the short-term treatment of symptomatic neurogenic orthostatic hypotension in
Parkinson’s disease (nOH306B). Mov Disord. 2015;30(5):646–54.
CAS
PubMed
Google Scholar
Kaufmann H, Freeman R, Biaggioni I, et al. Droxidopa for neurogenic
orthostatic hypotension: a randomized, placebo-controlled, phase 3 trial.
Neurology. 2014;83(4):328–35.
CAS
PubMed
PubMed Central
Google Scholar
Biaggioni I, Arthur Hewitt L, Rowse GJ, Kaufmann H. Integrated
analysis of droxidopa trials for neurogenic orthostatic hypotension. BMC Neurol.
2017;17(1):90.
PubMed
PubMed Central
Google Scholar
Hauser RA, Biaggioni I, Hewitt LA, Vernino S. Integrated analysis
of droxidopa for the treatment of neurogenic orthostatic hypotension in patients
with Parkinson disease. Mov Disord Clin Pract.
2018;5(6):627–34.
PubMed
PubMed Central
Google Scholar
François C, Shibao CA, Biaggioni I, et al. Six-month use of
droxidopa for neurogenic orthostatic hypotension. Mov Disord Clin Pract.
2019;6(3):235–42.
PubMed
Google Scholar
Hauser RA, Heritier S, Rowse GJ, Hewitt LA, Isaacson SH. Droxidopa
and reduced falls in a trial of Parkinson patients with neurogenic orthostatic
hypotension. Clin Neuropharmacol. 2016;39(5):220–6.
CAS
PubMed
PubMed Central
Google Scholar
Palma JA, Norcliffe-Kaufmann L, Martinez J, Kaufmann H. Supine
plasma NE predicts the pressor response to droxidopa in neurogenic orthostatic
hypotension. Neurology. 2018;91(16):e1539–44.
CAS
PubMed
PubMed Central
Google Scholar
Chen JJ, Han Y, Tang J, Portillo I, Hauser RA, Dashtipour K.
Standing and supine blood pressure outcomes associated with droxidopa and
midodrine in patients with neurogenic orthostatic hypotension: a Bayesian
meta-analysis and mixed treatment comparison of randomized trials. Ann
Pharmacother. 2018;52(12):1182–94.
CAS
PubMed
Google Scholar
Wright RA, Kaufmann HC, Perera R, et al. A double-blind,
dose-response study of midodrine in neurogenic orthostatic hypotension.
Neurology. 1998;51(1):120–4.
CAS
PubMed
Google Scholar
Low PA, Gilden JL, Freeman R, Sheng KN, McElligott MA. Efficacy of
midodrine vs placebo in neurogenic orthostatic hypotension. A randomized,
double-blind multicenter study. Midodrine Study Group. JAMA.
1997;277(13):1046–51.
CAS
PubMed
Google Scholar
Eschlbock S, Wenning G, Fanciulli A. Evidence-based treatment of
neurogenic orthostatic hypotension and related symptoms. J Neural Transm
(Vienna). 2017;124(12):1567–605.
PubMed
PubMed Central
Google Scholar
AvKARE, Inc. AvPAK (fludrocortisone acetate). Full prescribing
information. Pulaski: AvKARE, Inc.; 2018.
Google Scholar
Valeant Pharmaceuticals North America LLC. Mestinon
(pyridostigmine). Prescribing information, Bridgewater: Valeant Pharmaceuticals
North America LLC; 2013.
Shibao C, Gamboa A, Diedrich A, et al. Acarbose, an
alpha-glucosidase inhibitor, attenuates postprandial hypotension in autonomic
failure. Hypertension. 2007;50(1):54–61.
CAS
PubMed
Google Scholar
Ricci F, De Caterina R, Fedorowski A. Orthostatic hypotension:
epidemiology, prognosis, and treatment. J Am Coll Cardiol.
2015;66(7):848–60.
PubMed
Google Scholar
Ten Harkel AD, Van Lieshout JJ, Wieling W. Treatment of orthostatic
hypotension with sleeping in the head-up tilt position, alone and in combination
with fludrocortisone. J Intern Med. 1992;232(2):139–45.
PubMed
Google Scholar
Espay AJ, LeWitt PA, Hauser RA, Merola A, Masellis M, Lang AE.
Neurogenic orthostatic hypotension and supine hypertension in Parkinson’s
disease and related synucleinopathies: prioritisation of treatment targets.
Lancet Neurol. 2016;15(9):954–66.
PubMed
Google Scholar
Wieling W, Raj SR, Thijs RD. Are small observational studies
sufficient evidence for a recommendation of head-up sleeping in all patients
with debilitating orthostatic hypotension? MacLean and Allen revisited after
70 years. Clin Auton Res. 2009;19(1):8–12.
PubMed
Google Scholar
Jordan J, Fanciulli A, Tank J, et al. Management of supine
hypertension in patients with neurogenic orthostatic hypotension: scientific
statement of the American Autonomic Society, European Federation of Autonomic
Societies, and the European Society of Hypertension. J Hypertens.
2019;37(8):1541–6.
CAS
PubMed
Google Scholar